CrossRef Text and Data Mining
Result of CrossRef Text and Data Mining Search is the related articles with entitled article. If you click link1 or link2 you will be able to reach the full text site of selected articles; however, some links do not show the full text immediately at now. If you click CrossRef Text and Data Mining Download icon, you will be able to get whole list of articles from literature included in CrossRef Text and Data Mining.
Phase I Study of CKD-516, a Novel Vascular Disrupting Agent, in Patients with Advanced Solid Tumors
Do-Youn Oh, Tae-Min Kim, Sae-Won Han, Dong-Yeop Shin, Yun Gyoo Lee, Keun-Wook Lee, Jee Hyun Kim, Tae-You Kim, In-Jin Jang, Jong-Seok Lee, Yung-Jue Bang
Cancer Research and Treatment. 2016;48(1):28-36.   Published online 2015 February 23    DOI: https://doi.org/10.4143/crt.2014.258

Excel Download

Phase I Study of CKD-516, a Novel Vascular Disrupting Agent, in Patients with Advanced Solid Tumors
Cancer Research and Treatment. 2016;48(1):28-36   Crossref logo
Link1 Link2 Link3

Phase I Study of Ombrabulin, a Vascular Disrupting Agent (VDA), Administered Every 3 Weeks to Japanese Patients with Advanced Solid Tumors
Annals of Oncology. 2012;23:xi110   Crossref logo
Link1 Link2

Enhanced antitumor efficacy of a novel vascular disrupting agent (CKD-516) for transarterial infusion therapy in hepatocelluar carcinoma (HCC) model
Journal of Vascular and Interventional Radiology. 2014;25(3):S169   Crossref logo
Link1 Link2

A phase I study of MN-029 (denibulin), a novel vascular-disrupting agent, in patients with advanced solid tumors
Cancer Chemotherapy and Pharmacology. 2011;68(4):959-970   Crossref logo
Link1 Link2 Link3

359 POSTER Pharmacokinetic and pharmacodynamic effects of MN-029, a novel vascular disrupting agent (VDA), in patients (pts) with advanced solid tumors
European Journal of Cancer Supplements. 2006;4(12):111-112   Crossref logo
Link1 Link2

Chemoembolization with Vascular Disrupting Agent CKD-516 Dissolved in Ethiodized Oil in Combination with Doxorubicin: A VX2 Tumor Model Study
Journal of Vascular and Interventional Radiology. 2018;29(8):1078-1084   Crossref logo
Link1 Link2

Early quantification of the therapeutic efficacy of the vascular disrupting agent, CKD-516, using dynamic contrast-enhanced ultrasonography in rabbit VX2 liver tumors
Ultrasonography. 2013;33(1):18-25   Crossref logo
Link1 Link2

Phase I, dose-escalating study of elisidepsin (Irvalec®), a plasma membrane-disrupting marine antitumor agent, in combination with erlotinib in patients with advanced malignant solid tumors
Investigational New Drugs. 2015;34(1):75-83   Crossref logo
Link1 Link2 Link3

Phase I study of single-agent ribociclib in Japanese patients with advanced solid tumors
Cancer Science. 2017;109(1):193-198   Crossref logo
Link1 Link2

Phase I and pharmacokinetic study of the vascular‐disrupting agent CKD‐516 (NOV120401) in patients with refractory solid tumors
Pharmacology Research & Perspectives. 2020;8(2):   Crossref logo
Link1 Link2 Link3 Link4

This metadata service is kindly provided by CrossRef from May 29, 2014. Cancer Res Treat has participated in CrossRef Text and Data Mining service since October 29, 2014.